LA Universal Research Center, Inc.

The trials here

What the 7 trials at this site are about, from their registry records.

Conditions

• Atopic dermatitis (eczema)3 trials
• Chronic spontaneous urticaria2 trials
• Type 1 diabetes1 trial
• Type 2 diabetes1 trial
• Vitiligo1 trial

Phase

• Phase 34 trials
• Phase 22 trials

Status

• Active, not recruiting3 trials
• Completed2 trials
• Enrolling by invitation1 trial
• Recruiting1 trial

Lead sponsor

• Celldex Therapeutics3 trials
• Eli Lilly and Company1 trial
• Incyte Corporation1 trial
• Senseonics, Inc.1 trial
• UNION therapeutics1 trial

Running trials

• Enrolling by invitation

  Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria

  NCT07256392· Phase 3· Celldex Therapeutics· Source

• Recruiting

  A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo

  NCT06548360· Phase 3· Incyte Corporation· Source

• Active, not recruiting

  A Study of Barzolvolimab in Patients With Atopic Dermatitis

  NCT06727552· Phase 2· Celldex Therapeutics· Source

• Active, not recruiting

  A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU)

  NCT06455202· Phase 3· Celldex Therapeutics· Source

• Active, not recruiting

  Eversense® Non-adjunctive Use Post Approval Study

  NCT04836546· Senseonics, Inc.· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Chronic spontaneous urticaria1 recruiting
• Vitiligo1 recruiting

Closed trials

• Completed

  Study to Assess the Efficacy and Safety of Orismilast in Atopic Dermatitis (ADESOS)

  NCT05469464· Phase 2· UNION therapeutics· Source

• Completed

  Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin)

  NCT04392154· Phase 3· Eli Lilly and Company· Source